**Supplementary Table 1.** Renal relapse according to ANCA at diagnosis and ANCA persistence at remission.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | ANCA at DIAGNOSIS | | | ANCA persistence AT REMISSION\* | | |
|  | PR3-ANCA+ | MPO-ANCA+ | ANCA- | PR3-ANCA+ | MPO-ANCA+ | ANCA- |
| H- | 6 / 20 | 4 / 23 | 0 / 2 | 3 / 7 | 3 / 15 | 2 / 13 |
| H+ | 11 / 21 | 4 / 18 | 1 / 2 | 8 / 14 | 3 / 12 | 3 / 7 |

H−/+, Patients without/with hematuria at remission; PR3, proteinase 3; MPO: myeloperoxidase; ANCA-/+, absence/presence (PR3 or MPO-ANCA) of antineutrophil cytoplasmic antibodies; \*Missing data for ANCA persistence at remission = 18. Data are reported as number of relapses/total number of patients in each sub-group.

C:\Users\vandenbussche-c\Desktop\Article\final devis\Supplementary Material-sup_figure_2.tifC:\Users\vandenbussche-c\Desktop\Article\final devis\Supplementary Material-sup_figure_1.tif

**Supplementary figure 1.** Flow-chart. Group without (H-) or with (H+) hematuria at remission.

**Supplementary figure 2.** Kaplan-Meier survival curves for renal relapse according to ANCA type (MPO or PR3) (A) at diagnosis and (B) in association to hematuria at remission.